Purpose of Review Metastatic colorectal cancer (CRC) is a vexing clinical problem. In contrast to early-stage disease, once CRC metastasizes to other organs, long-term survival is compromised. We seek to review the molecular pathogenesis, animal models, and functional genomics for an enhanced understanding of how CRC metastasizes and how this can be exploited therapeutically. Recent Findings Mouse models may recapitulate certain aspects of metastatic human CRC and allow for studies to identify regulators of metastasis. Modulation of transcription factors, onco-proteins, or tumor suppressors has been identified to activate known metastatic pathways. CD44 variants, microRNAs, and RNA binding proteins are emerging as metastatic modulators. Summary CRC metastasis is a multi-faceted and heterogeneous disease. Despite common pathways contributing to metastatic development, there are numerous variables that modulate metastatic signals in subsets of patients. It is paramount that studies continue to investigate metastatic drivers, enhancers, and inhibitors in CRC to develop therapeutic targets and improve disease outcomes.
Introduction
There are approximately 140,000 new cases of colorectal cancer (CRC) in the USA and an estimated 1.4 million cases annually worldwide [1] . Despite significant advances in the prevention, screening, and surveillance of CRC in the USA, annual mortality has remained relatively constant at about 50,000 deaths/year, and thus, CRC is one of the leading causes of cancer-related mortality [1] . In CRC, mortality is related typically to metastasis to distant organs, far exceeding mortality that is the consequence of primary disease. Five-year survival rates are favorable for stages I and II [2] . However, stage IV CRC is beset by challenges in early detection and therapy.
Metastasis formation is a multi-step process involving invasion of primary tumor cells through the basement membrane and intravasation into nearby lymphatics or blood vessels. These tumor cells must then survive transport to distant organ sites (typically liver in CRC) where they extravasate and colonize the secondary organ site to establish micrometastases. Micro-metastases proliferate to expand at the secondary site, albeit depending upon the tumor type, there may be periods of dormancy. There is a compelling need to illuminate and amplify our understanding of the molecular mechanisms underlying metastatic CRC and to translate this knowledge into new perspectives on prognosis, risk stratification, and therapy.
This review covers the salient features of animal models and key signaling pathways that have been implicated in metastatic CRC with a focus on in vivo model systems whenever feasible. However, we appreciate that this review will not be able to cover all topics in metastatic CRC, especially as they relate to current therapies.
Mouse Models of Metastasis
There are a variety of mouse models of CRC metastasis, including xenograft models where tumor cells are injected into the circulation or implanted into the cecum or colon, as well as genetically engineered mouse models (GEMMs), which carry a number of conditional genetic mutations that, when induced, This article is part of the Topical Collection on Basic Science Foundations in Colorectal Cancer result in metastasis formation [3, 4•] . Xenograft models are often immune-compromised, which allows for experimentation with human cells but eliminates the immune system component from disease progression. Direct injection of tumor cells into the cecal or colonic wall or into the circulation also bypasses some or many of the steps involved in metastasis formation. GEMMs can recapitulate the progression from adenoma to metastatic cancer; however, they are expensive and can have long latency.
Implantable mouse models have been long-standing in cancer biology, let alone in CRC. These involve xenografts in which human CRC lines, patient tumor cells [ [15] .
Genetic mouse models of CRC involve manipulation of key oncogenes (e.g., mutant Kras, mutant Braf) and tumor suppressor genes (Apc, Trp53, Tgfbr2/Smad4). One principle appears to be that activation of individual oncogenes or inactivation of tumor suppressor genes is insufficient to yield metastasis. For example, neither mutant KRAS nor mutant BRAF can promote substantial primary tumorigenesis let alone metastatic tumors [16] . These may be due in part to oncogene-mediated senescence or lack of expansion of mutant stem cell clones that require additional genetic alterations to overcome these barriers [17, 18] . To that end, deletion of Ink4a/Arf in K-ras G12D mice surmounts senescence and leads to invasive and metastatic cancers [19] and oncogenic Braf V600E mutation coupled with microsatellite instability, p16
Ink4a inactivation, and Trp53 mutation results in the emergence of primary and metastatic tumors [20, 21] . Interestingly, these two genetic models share the development and characterization of the sessile serrated adenoma pathway to CRC.
Other examples of phenocopying metastatic CRC ( 
Signaling Pathways that Drive or Enhance CRC Metastasis

WNT/β-Catenin
Certainly, the afore-mentioned mouse models underscore the importance of activated WNT signaling in both colorectal tumor initiation and tumor metastasis. In this context, nuclear translocation and accumulation of β-catenin is important, with resulting induction of numerous gene targets that foster proliferation and growth. BCL9-2, a β-catenin binding protein, may be part of a regulatory network that modulates β-catenin's cellular adhesive properties versus transcriptional functions [28] . Studies reveal variable nuclear β-catenin in both primary and metastatic colorectal tumors, with more prominent accumulation in invasive tumor fronts, thereby reflecting tumor heterogeneity [29] and cell stemness [30] .
WNT/β-catenin signaling is central to a number of pathways that contribute to the metastatic progression of CRC. For example, DACT2 is a tumor suppressor that directly inhibits WNT/β-catenin signaling and when lost enhances metastasis [31] . The transcription factor PROX1 is downstream of WNT and promotes survival of WNT-high tumor-initiating cells in metabolically stressed environments. Targeting PROX1 or downstream effectors are viable therapeutic options for patients who have developed anti-EGFR therapy resistance but have PROX1 positivity [32] . The GTPase RhoA acts upstream of β-catenin to maintain membranous localization. Loss of RhoA leads to accumulation of nuclear β-catenin and enhances metastasis formation in xenograft mouse models [33] . Identifying patients with nuclear β-catenin levels is critical to determining effective therapy options, as use of the AKT inhibitor (API-2) has been shown to promote cell survival and metastasis in PDX models through synergistic interactions with nuclear β-catenin and FOXO3a [34] . While inhibitors of WNT signaling are used in preclinical models, they
are not yet advanced in clinical trials.
TGF-β Pathway
This pathway and its principle components-receptors types I and II, SMAD3 and SMAD4, are altered in different stages of CRC. Mutations in TGF-β type II receptor are associated with microsatellite instability [35] . Given the pleotropic effects of TGF-β signaling in normal intestinal epithelial homeostasis and in malignant cells, it should be noted that these effects are cell autonomous and non-cell autonomous. One striking finding is that TGF-β signaling affects stromal cells to "prime" metastatic colonization by CRC cells [36] . This is mediated by secretion of IL-11 from cancer-associated fibroblasts stimulated by TGF-β with resulting GP130/STAT3 signaling in the tumor cells. Pharmacological inhibition of TGF-β signaling limited metastasis formation [36] . The role of epithelial TGF-β in metastasis is not clear. Several studies suggest that TGF-β signaling is protective against metastatic CRC [22•, 37, 38] . Conversely, others have shown that TGF-β promotes metastatic spread downstream of mutant KRAS [25] , suggesting that caution must be exercised if targeting TGF-β to prevent metastatic spreads. Neutralizing antibodies targeting TGF-β ligand(s) or inhibitors of components of the TGF-β pathway are conceptually appealing and remain investigational, largely speaking.
KRAS/BRAF
KRAS mutations are a common hallmark of CRC progression, where the mutated GTPase is permanently stuck in an activated state [39] . Although dispensable for primary tumor growth [22•, 25, 26] , mutant Kras appears to be a strong driver of invasion and metastasis [19, 22•, 25, 26] . The combination of mutant Kras with other genetic alterations is evidenced also when combined Tgfr2 resulting in metastatic tumors to the lymph nodes and lungs [24] . An intrasplenic injection xenograft model demonstrated that ERK2 activation (in a mutant KRAS background) specifically facilitates liver metastases, while inhibition of p38/MAPK signaling specifically enhances lung metastases [40] . Loss of p38 promotes secretion of PTHLH, which causes caspase-independent apoptosis of the lung microvasculature, facilitating extravasation of the tumor cells into the lung tissue [40] .
BRAF is one of three protein kinases in the MAPK signaling pathway [41] . Mutations in BRAF are strongly associated with poor prognosis [41] and are prevalent in patients with high microsatellite instability (MSI-H). Animal models demonstrate that selective expression of mutant Braf in the intestinal and colonic epithelium does promote tumor formation with some lymph node involvement [20] . Mutant Braf combined with either a Trp53 or Cdkn2a (p16) mutation greatly enhances metastatic spread [20] . There are several therapeutic options for patients with BRAF mutations, including combinations of conventional chemotherapeutics [41] . Recent studies have focused on therapies combining BRAF and EGFR inhibitors with MEK, PI3K, or WNT inhibition [41] .
Hepatocyte Growth Factor (HGF)/MET
The hepatocyte growth factor (HGF) acts via binding its cognate receptor tyrosine kinase, MET, which is critical to embryonic development and hyper-activated in primary CRC tumor development and metastasis [42] . MET is a major signaling node that when activated promotes CRC metastasis. Recent studies have identified a number of transcription factors that directly facilitate MET expression, promote metastasis in in vivo models, and whose expression is elevated in metastatic patient samples. FOXC2 directly targets MET to promote metastasis in vivo [43] . The transcription factor metastasisassociated in colon cancer-1 (MACC1) [44] directly binds to the MET promoter to enhance transcription in an HGFdependent manner. Several studies have demonstrated that targeting MACC1 genetically or chemically reduces metastases in animal models [45, 46] . Interestingly, lovastatin and rottlerin are small-molecule inhibitors of MACC1 [46] . These are FDA-approved compounds, which could be repositioned for use in metastatic CRC patients. Although patients who use statins have a reduced risk of developing CRC, statins have shown poor efficacy in the clinic for treating CRC. Perhaps stratifying patients based on MACC1 expression will improve clinical outcomes for this subset of patients [46] .
Signaling through MET is not only controlled by receptor expression but also by structural components that facilitate HGF ligand binding. CD44 is an alternatively spliced, transmembrane glycoprotein that is highly expressed in intestinal stem cells and adenomas and acts as a co-receptor for receptor tyrosine kinases, as well as other signaling molecules (reviewed by [47] ). Enhanced splicing variation is associated with tumor aggressiveness in CRC patients [48] , and CD44 variant expression promotes adenoma formation in Apc Min/+ mice [49, 50] . CD44 variants and MET together promote the growth of ex vivo adenoma organoid cultures, and the variant CD44v6 is required for HGF/MET signaling [51, 52] . It was shown that patient metastases were enriched for cells expressing CD44v6 and that these cells were responsible for metastasis formation in mice. is not only involved in HGF/MET signaling but is also upstream of a number of other oncogenic mediators, including cMyc and STAT3, which promote metastasis of CRC cells via ankoikis resistance and enhancing EMT properties [53] .
There are a number of therapeutic approaches that have been developed to target CD44 variants, including methods that disrupt binding to hyaluronic acid (antibodies, soluble competitive ectodomains, or nanoparticle-infused chemotherapeutic delivery), monoclonal antibodies, aptamers that inhibit binding functions, blocking peptides, and methods for blocking CD44 expression, including si-and shRNA delivery (reviewed by [47] ). Future studies could focus on identifying and targeting isoform-and tumor-specific CD44-mediated effects.
PI3K/AKT/mTOR
The PI3K/AKT pathway propagates signals from growth factors, cytokines, and oncogenic-mediators to contribute to CRC pathogenesis. The tumor suppressor PTEN inhibits PI3K/AKT signaling. Loss of PTEN promotes metastasis in CRC [54] as does expression of the adaptor protein paxillin [55] , both of which activate PI3K/AKT signaling. AKT2, which is highly expressed in late stage CRC, is essential for establishment of liver metastases and when combined with the loss of PTEN further enhances metastasis in the intrasplenic injection model [56] . IL13 also induces PI3K/AKT and signal propagation relies in part on the scaffolding protein FAM120A. FAM120A stabilizes multi-protein complexes allowing for transmission of metastatic signals [57] . Loss of FAM120A alone or in combination with IL13Ra2 inhibition enhanced the survival of mice in an intrasplenic injection model of liver metastasis [57] . Targeting PI3K itself or the downstream effector mTOR has proven effective for reducing metastasis in animal models [58, 59] . Previous attempts to use rapamycin to target mTORC1 in CRC patients have not been fruitful; however, dual targeting of mTORC1 and 2 may yield more favorable outcomes [59] . Combination targeting of mTOR and other molecules, such as stromal target PDGF, may also improve outcomes [60] .
Epidermal Growth Factor Receptor (EGFR)
While the epidermal growth factor receptor (EGFR) is a known contributor to the development of primary CRC [61] and is targeted therapeutically with antibodies or small molecule inhibitors [62] , there is a lack of model systems that link EGFR signaling directly to CRC metastasis. A variety of studies provide correlative evidence for EGFR expression in advanced [63] or metastatic CRC [64] . EGFR expression is correlated with worse prognosis [65] . Enhanced EGFR signaling may partially contribute to lung metastasis in a mouse model of metastatic colon cancer (VilCre;Tgfbr2 f/f ;Kras LSL-G12D/+ ) [24] . Since EGFR expression does not necessarily predict response to therapy [66] , it is possible and likely that EGFR signaling in non-epithelial tissues is contributing to tumor progression. Recent work has demonstrated that EGFR expression on myeloid cells promoted tumor growth in a mouse model of inflammation-associated cancer [67] . The detection of EGFR on circulating extracellular vesicles isolated from the blood of xenograft mice bearing CRC cell line tumors is an example of the ongoing optimization of liquid biopsy methods for early CRC detection and monitoring [68] .
Global Metastasis Modulators: microRNAs and RNA Binding Proteins miRNAs microRNAs (miRNAs) are important regulators of gene expression as they modulate multiple targets within a signaling pathway simultaneously. The processing and maturation of miRNAs are dependent upon the activity of the enzyme DICER and modulations in DICER expression and/or activity alter the available miRNA pool. Loss of DICER promotes metastasis in many tissue types, including from the colon [69, 70] . Loss of DICER enhances a tumor-initiating cell population, increases markers of epithelial to mesenchymal transition, and promotes metastasis via downregulation of tumor suppressor miRNAs (miR-126, miR-34a, and miR-335) [69] .
While the body of literature on miRNAs and CRC is extensive, we will highlight certain miRNAs (miR-34a and miR15a/16-1) that have been validated in animal models as playing direct roles in CRC metastasis. The miR-34a is a tumor suppressor that acts downstream of the IL-6/STAT3 pathway to inhibit epithelial to mesenchymal transition, invasion, and metastasis. IL-6 represses miR-34a directly via STAT3 and treating CRC cells with IL-6 enhances lung metastasis in a tail vein injection model [71] . Loss of STAT3 or IL-6R inhibits metastasis, and loss of miR-34a promotes invasion in the dextran-sodium sulfate mouse model of inflammation-associated CRC [71] . In humans, silencing of miR-34a has been associated with lymph node involvement and distant metastases in human patient samples [72] . Administration of miR-34a to mice inhibited metastasis of prostate cancer cells to the lung, in part through direct targeting of CD44 [73] .
miR-15a/16-1 are also tumor suppressive miRNAs that inhibit transcription of AP4 [74] . AP4 has been previously shown to promote metastasis [75] , and ectopic expression of miR-15a/16-1 limits AP4-mediated metastasis in the tail vein injection model [74] .
mRNA Binding Proteins
Like miRNAs, RNA binding proteins (RBPs) can also regulate entire signaling pathways. RBPs can modulate the location, maturation, stability, and/or translation of target mRNAs [76] . We have identified LIN28B, a pluripotency factor and inhibitor of miRNA let-7 biogenesis, as a promoter of metastasis in CRC. Using a variety of human CRC cell lines, we demonstrated that LIN28B expression promoted metastasis in vivo in the subcutaneous xenograft model where metastases are less common [77] . Additionally, we have shown that expression of the RNA binding protein insulin-like growth factor 2 mRNA binding protein 1 (IMP1) is significantly increased in lymph node involved tissues from CRC patients [78] , suggesting a role for IMP1 in CRC metastasis. IMP1 expression correlates with poor prognosis, reduced survival, and increased metastasis in CRC patient samples and promotes a metastatic phenotype in vitro [79, 80] . Expression of another IMP isoform, IMP3, correlates with worse prognosis, reduced survival, and increased metastasis in CRC [81, 82] , while expression of ELAV-like protein 1 (HUR) expression is correlated with poor survival in CRC, but not metastasis specifically [83] .
The Musashi family of RNA binding proteins is required for intestinal tumorigenesis [84] and plays important roles in CRC tumor formation and progression by targeting a number of key signaling pathways, including Notch [85] , WNT [85] , PTEN/mTOR [84, 86] , TGF-β/SMAD3, MYC, and MET [86, 87] . Similar to IMP1, IMP3, and HUR, Mushashi-1 and -2 expression is also highly correlated with poor prognosis, reduced disease-free survival, lymph node involvement, and liver metastases in CRC patients [88, 89] ; however, there are no studies that examine the direct impact of Musashi on CRC metastasis.
A closer examination of direct roles for these RNA binding proteins in CRC metastasis is warranted, as targeting an RNA binding protein could silence oncogenic signaling at multiple points, rather than targeting a single protein in a given pathway. For example, studies demonstrate that IMP1 targets KRAS [90, 91] , CD44 [90, 92] , and other oncogenic mediators suggesting that targeting IMP1 in certain circumstances may also be beneficial to limiting CRC progression. Recent work has identified an IMP1 inhibitor in ovarian and melanoma cells [93] and described IMP1 inhibition as enhancing treatment efficacy in BRAF V600E melanoma [94] . Targeting Musashi could simultaneously shutdown metastatic signals through Notch, WNT, mTOR, TGF-β, myc, and MET. Efforts to identify Musashi inhibitors are underway and demonstrate its utility as a target; however, candidate approaches are still in the discovery stage or animal model testing (reviewed in [87] ).
Conclusion
Recent work demonstrates a growing understanding of molecular drivers and enhancers of metastasis in CRC (Fig. 1) . Current efforts on GEMMs, humanized animal models with patient-derived tumor cells, 3D organoids, identification of new biomarkers, and testing of potential therapeutics will advance the field. Metastases typically result from the culmination of many aberrant signaling events rather than a single mutation or abnormal protein, and this progression is highly variable between patients. Focusing the development of therapeutics on targeting broad metastatic regulators, such as miRNAs or mRNA binding proteins, may have a greater impact than targeting a single protein within a signaling cascade. Developing diagnostic and prognostic markers from liquid biopsy or from markers of metastatic potential within the primary tumor may allow for personalized medicine. Using patient-derived tumor cells, rather than cell lines, to test therapies should also improve our ability to rapidly identify and validate new targets. , and Smad4, which were generated through a combination of mouse genetics and CRISPR/Cas9 technology. Using these tools they demonstrated that Lgr5+ cells initiate tumor formation and metastasis, but that ablation of Lgr5+ cells within a formed tumor only slows tumor growth and does not lead to tumor regression.
